Nuvonis Technologies

Nuvonis is a Austrian biotechnology company specializing in high-performance host cell lines and GMP-compliant cell bank systems used in the development and industrial manufacturing of viral vaccines, viral vectors, and biopharmaceuticals.

1. GMP & R&D Cell Banks (Vero & Avian)

Nuvonis provides fully characterized, ready-to-use Master Cell Banks (MCBs) and Working Cell Banks (WCBs) produced under serum-free and animal-component-free conditions.

• Vero Cell Banks: Used as host substrates for manufacturing a wide spectrum of human and veterinary viral vaccines and vectors.

• Avian Cell Banks: Designed as continuous substrates for propagating specific viral strains (e.g., Vaccinia, MVA, HSV, Parainfluenza, Newcastle Disease Virus).

2. Process Development Services

Beyond offering off-the-shelf cell banks, Nuvonis supports clients in upstream and downstream process development. This includes optimizing viral production yields, adapting cell lines to serum-free suspension growth, and scaling up manufacturing processes.

3. Biopharmaceutical & CMC Consulting

The company leverages its internal regulatory and technical expertise to offer biopharmaceutical consulting. Services range from CMC (Chemistry, Manufacturing, and Controls) support and CDMO management to regulatory filing strategies for clinical trial applications.